Similarly, in hepatocellular carcinoma, the development of lenvatinib resistance is closely associated with the aberrant activation of the AHR-AREG-EGFR-ERK1/2-Cyclin D1 signaling axis. This evidence concerns the gene AHR and hepatocellular carcinoma.